HNRNPA1 and hepatocellular carcinoma: It has been reported that TKP significantly reduces β-catenin expression in a dose-dependent manner and inhibits the β-catenin/c-Myc/hnRNPA1 signaling cascade, thereby inhibiting glycolysis and cell proliferation of hepatocellular carcinoma cells [44].